Cutler Group’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-500
Closed -$4K 3736
2023
Q2
$4K Sell
500
-17,300
-97% -$77.7K ﹤0.01% 2673
2023
Q1
$31K Buy
17,800
+12,200
+218% +$145K ﹤0.01% 1647
2022
Q4
$1K Buy
5,600
+500
+10% +$5.62K ﹤0.01% 3883
2022
Q3
$11K Buy
+5,100
New +$75.3K ﹤0.01% 3043
2021
Q4
Sell
-17,200
Closed -$2K 5309
2021
Q3
$2K Buy
17,200
+4,900
+40% +$59.6K ﹤0.01% 4955
2021
Q2
$10K Buy
+12,300
New +$168K ﹤0.01% 3870
2020
Q4
Sell
-2,200
Closed -$2K 4745
2020
Q3
$2K Sell
2,200
-2,200
-50% -$44K ﹤0.01% 3977
2020
Q2
$3K Buy
+4,400
New +$24.2K ﹤0.01% 3556

Other funds holding ALT

Cutler Group's ALT Position: Q1 2024 in Review

Cutler Group reduced its Altimmune (ALT) stake by 77% in Q1 2024, selling an estimated $17.3K and leaving 500 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1536.

Cutler Group first reported a position in ALT in Q1 2020 and has held it in 15 quarters since. The position peaked at $326K in Q3 2022. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Cutler Group held 500 shares of Altimmune worth $5K as of Q1 2024.
  • Cutler Group sold 1,700 Altimmune shares in Q1 2024, an estimated $17.3K.
  • Altimmune made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1536 holding.
  • Cutler Group first reported a position in Altimmune in Q1 2020 and has held it in 15 quarters since.
  • Cutler Group's Altimmune position peaked at $326K in Q3 2022.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.